The emergence of data from clinical trials of biologics, the approval of new biologics, and
our improved understanding of psoriasis pathogenesis have increased the therapeutic …

A subset of patients with ulcerative colitis (UC) present with, or progress to, moderate to
severe disease activity. These patients are at high risk for colectomy, hospitalization …

Objective To examine whether initiation of interleukin (IL)-17, IL-12/23 or tumour necrosis
factor (TNF) inhibitor is associated with an increased risk of serious infection among real …

Brodalumab is a recombinant, fully human monoclonal antibody (IgG2) which binds with
high affinity to the interleukin (IL) 17 receptor A (IL17R). Brodalumab is now licensed and …

Abstract Coronavirus disease 2019 (COVID‐19) is responsible for at least 2 546 527 cases
and 175 812 deaths as of April 21, 2020. Psoriasis and atopic dermatitis (AD) are common …

Psoriasis and psoriatic arthritis cause significant physical and psychological burdens for
afflicted individuals. An accelerated TNF-α/IL-23/IL-17 axis is their major pathomechanism; …

Abstract Biologics targeting Th1/Th17 cytokines have revolutionised psoriasis treatment. In
addition to treatment effectiveness, it is important to define and understand the long-term …

Introduction: Efficacy and safety are key aspects when choosing therapies for patients with
inflammatory bowel diseases (IBD). While several randomized trials and indirect …

Background Registry studies broadly describing the safety of systemic drugs in psoriasis are
needed. Objective To describe the safety findings of the systemic drugs acitretin …

Abstract Coronavirus disease (COVID‐19) is a highly contagious respiratory infection
caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2). COVID‐19 …